Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
Sudhan DR, Guerrero-Zotano A, Won H, González Ericsson P, Servetto A, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Red Brewer M, Dugger T, Koch J, Wick MJ, Cutler RE Jr, Lalani AS, Bryce R, Auerbach A, Hanker AB, Arteaga CL. Sudhan DR, et al. Among authors: servetto a. Cancer Cell. 2020 Feb 10;37(2):183-199.e5. doi: 10.1016/j.ccell.2019.12.013. Epub 2020 Jan 23. Cancer Cell. 2020. PMID: 31978326 Free PMC article.
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R. D'Amato V, et al. Among authors: servetto a. Br J Cancer. 2014 Jun 10;110(12):2887-95. doi: 10.1038/bjc.2014.241. Epub 2014 May 13. Br J Cancer. 2014. PMID: 24823695 Free PMC article.
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C, Rosa R, Marciano R, D'Amato V, Formisano L, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fulciniti F, Cipolletta A, Bianco C, Ciardiello F, Veneziani BM, De Placido S, Bianco R. D'Amato C, et al. Among authors: servetto a. Br J Cancer. 2014 Sep 9;111(6):1168-79. doi: 10.1038/bjc.2014.421. Epub 2014 Aug 5. Br J Cancer. 2014. PMID: 25093491 Free PMC article.
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R. Formisano L, et al. Among authors: servetto a. Oncotarget. 2015 Sep 22;6(28):26090-103. doi: 10.18632/oncotarget.4636. Oncotarget. 2015. PMID: 26325669 Free PMC article.
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.
Di Mauro C, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Formisano L, De Falco S, Cicatiello V, Di Bonito M, Cantile M, Collina F, Chambery A, Veneziani BM, De Placido S, Bianco R. Di Mauro C, et al. Among authors: servetto a. Br J Cancer. 2017 May 23;116(11):1425-1435. doi: 10.1038/bjc.2017.116. Epub 2017 Apr 25. Br J Cancer. 2017. PMID: 28441382 Free PMC article.
ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.
Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL. Guerrero-Zotano AL, et al. Among authors: servetto a. Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26. Clin Cancer Res. 2018. PMID: 29581135 Free PMC article.
Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.
Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL. Guerrero-Zotano AL, et al. Among authors: servetto a. Clin Cancer Res. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270. Clin Cancer Res. 2019. PMID: 30770490 Free PMC article. No abstract available.
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL. Formisano L, et al. Among authors: servetto a. Nat Commun. 2019 Mar 26;10(1):1373. doi: 10.1038/s41467-019-09068-2. Nat Commun. 2019. PMID: 30914635 Free PMC article.
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.
Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. Drago JZ, et al. Among authors: servetto a. Clin Cancer Res. 2019 Nov 1;25(21):6443-6451. doi: 10.1158/1078-0432.CCR-19-0138. Epub 2019 Aug 1. Clin Cancer Res. 2019. PMID: 31371343 Free PMC article.
Mechanisms of resistance to mTOR inhibitors.
Formisano L, Napolitano F, Rosa R, D'Amato V, Servetto A, Marciano R, De Placido P, Bianco C, Bianco R. Formisano L, et al. Among authors: servetto a. Crit Rev Oncol Hematol. 2020 Mar;147:102886. doi: 10.1016/j.critrevonc.2020.102886. Epub 2020 Jan 29. Crit Rev Oncol Hematol. 2020. PMID: 32014673 Review.
52 results